Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Acute HIV in an Adolescent Male With Fever and Rhabdomyolysis.

Same RG, McAleese S, Agwu AL, Arav-Boger R.

J Adolesc Health. 2019 Aug 7. pii: S1054-139X(19)30311-8. doi: 10.1016/j.jadohealth.2019.05.021. [Epub ahead of print]

PMID:
31401024
2.

Prevalence, Magnitude, and Genotype Distribution of Urinary Cytomegalovirus (CMV) Shedding Among CMV-Seropositive Children and Adolescents in the United States.

White JL, Patel EU, Abraham AG, Grabowski MK, Arav-Boger R, Avery RK, Quinn TC, Tobian AAR.

Open Forum Infect Dis. 2019 Jun 5;6(7):ofz272. doi: 10.1093/ofid/ofz272. eCollection 2019 Jul.

3.

Evaluating congenital syphilis in a reverse sequence testing environment.

Chen MW, Akinboyo IC, Sue PK, Donohue PK, Ghanem KG, Detrick B, Witter FR, Page KR, Arav-Boger R, Golden WC.

J Perinatol. 2019 Jul;39(7):956-963. doi: 10.1038/s41372-019-0387-9. Epub 2019 May 10.

PMID:
31076626
4.

Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of In Vitro Screenings.

Jackson JW, Hancock TJ, Dogra P, Patel R, Arav-Boger R, Williams AD, Kennel SJ, Wall JS, Sparer TE.

mSphere. 2019 Feb 13;4(1). pii: e00586-18. doi: 10.1128/mSphere.00586-18.

5.

Blood Viral Load in Symptomatic Congenital Cytomegalovirus Infection.

Marsico C, Aban I, Kuo H, James SH, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth S, Jester PM, Whitley RJ, Kimberlin DW; Collaborative Antiviral Study Group (CASG).

J Infect Dis. 2019 Apr 16;219(9):1398-1406. doi: 10.1093/infdis/jiy695.

PMID:
30535363
6.

Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.

Nelson CS, Vera Cruz D, Su M, Xie G, Vandergrift N, Pass RF, Forman M, Diener-West M, Koelle K, Arav-Boger R, Permar SR.

J Virol. 2019 Feb 19;93(5). pii: e01695-18. doi: 10.1128/JVI.01695-18. Print 2019 Mar 1.

7.

Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides.

Wang Y, Mukhopadhyay R, Roy S, Kapoor A, Su YP, Charman SA, Chen G, Wu J, Wang X, Vennerstrom JL, Arav-Boger R.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01735-18. doi: 10.1128/AAC.01735-18. Print 2019 Jan.

8.

Maternal and fetal cytomegalovirus infection: diagnosis, management, and prevention.

Pass RF, Arav-Boger R.

F1000Res. 2018 Mar 1;7:255. doi: 10.12688/f1000research.12517.1. eCollection 2018. Review.

9.

A 17-Year-Old Boy With Right Face Palsy, Left Leg Weakness, and Lytic Skull-Bone Lesions.

Akinboyo IC, Crane GM, Chen L, Arav-Boger R.

J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):350-354. doi: 10.1093/jpids/pix101.

PMID:
29373673
10.

Digitoxin Suppresses Human Cytomegalovirus Replication via Na+, K+/ATPase α1 Subunit-Dependent AMP-Activated Protein Kinase and Autophagy Activation.

Mukhopadhyay R, Venkatadri R, Katsnelson J, Arav-Boger R.

J Virol. 2018 Feb 26;92(6). pii: e01861-17. doi: 10.1128/JVI.01861-17. Print 2018 Mar 15.

11.

Placental pericytes and cytomegalovirus infectivity: Implications for HCMV placental pathology and congenital disease.

Aronoff DM, Correa H, Rogers LM, Arav-Boger R, Alcendor DJ.

Am J Reprod Immunol. 2017 Sep;78(3). doi: 10.1111/aji.12728. Epub 2017 Jul 25.

12.

The effect of a genetic variant on quantitative real-time PCR in a case of disseminated adenovirus infection.

Gniadek TJ, Forman MT, Martin I, Arav-Boger R, Valsamakis A.

Diagn Microbiol Infect Dis. 2017 Sep;89(1):40-43. doi: 10.1016/j.diagmicrobio.2017.05.013. Epub 2017 Jun 1.

PMID:
28629877
13.

Cytomegalovirus Kinetics Following Primary Infection in Healthy Women.

Forman MS, Vaidya D, Bolorunduro O, Diener-West M, Pass RF, Arav-Boger R.

J Infect Dis. 2017 May 15;215(10):1523-1526. doi: 10.1093/infdis/jix188.

14.

Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Cui X, Adler SP, Schleiss MR, Arav-Boger R, Demmler Harrison GJ, McVoy MA.

Clin Vaccine Immunol. 2017 Jun 5;24(6). pii: e00024-17. doi: 10.1128/CVI.00024-17. Print 2017 Jun.

15.

Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization.

Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R.

Clin Cancer Res. 2017 Jun 15;23(12):3150-3157. doi: 10.1158/1078-0432.CCR-16-1490. Epub 2016 Dec 29.

16.

Role of nucleotide-binding oligomerization domain 1 (NOD1) and its variants in human cytomegalovirus control in vitro and in vivo.

Fan YH, Roy S, Mukhopadhyay R, Kapoor A, Duggal P, Wojcik GL, Pass RF, Arav-Boger R.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7818-E7827. Epub 2016 Nov 16.

17.

Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.

Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, Trollinger B, Shah P, Ambinder R, Neofytos D, Ostrander D, Forman M, Valsamakis A.

Transplantation. 2016 Oct;100(10):e74-80. doi: 10.1097/TP.0000000000001418.

18.

Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus.

Mukhopadhyay R, Roy S, Venkatadri R, Su YP, Ye W, Barnaeva E, Mathews Griner L, Southall N, Hu X, Wang AQ, Xu X, Dulcey AE, Marugan JJ, Ferrer M, Arav-Boger R.

PLoS Pathog. 2016 Jun 23;12(6):e1005717. doi: 10.1371/journal.ppat.1005717. eCollection 2016 Jun.

19.

Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children.

Barger-Kamate B, Forman M, Sangare CO, Haidara AS, Maiga H, Vaidya D, Djimde A, Arav-Boger R.

J Clin Virol. 2016 Apr;77:40-5. doi: 10.1016/j.jcv.2016.02.006. Epub 2016 Feb 11.

20.

Cytomegalovirus Enterocolitis in Immunocompetent Young Children: A Report of Two Cases and Review of the Literature.

Sue PK, Salazar-Austin NM, McDonald OG, Rishi A, Cornish TC, Arav-Boger R.

Pediatr Infect Dis J. 2016 May;35(5):573-6. doi: 10.1097/INF.0000000000001080. Review.

21.

Bacterial Muramyl Dipeptide (MDP) Restricts Human Cytomegalovirus Replication via an IFN-β-Dependent Pathway.

Kapoor A, Fan YH, Arav-Boger R.

Sci Rep. 2016 Feb 2;6:20295. doi: 10.1038/srep20295.

22.

Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs.

Fox JM, Moynihan JR, Mott BT, Mazzone JR, Anders NM, Brown PA, Rudek MA, Liu JO, Arav-Boger R, Posner GH, Civin CI, Chen X.

Oncotarget. 2016 Feb 9;7(6):7268-79. doi: 10.18632/oncotarget.6896.

23.
24.

Strain Variation and Disease Severity in Congenital Cytomegalovirus Infection: In Search of a Viral Marker.

Arav-Boger R.

Infect Dis Clin North Am. 2015 Sep;29(3):401-14. doi: 10.1016/j.idc.2015.05.009. Epub 2015 Jul 4. Review.

25.

Broad-spectrum non-nucleoside inhibitors of human herpesviruses.

McClain L, Zhi Y, Cheng H, Ghosh A, Piazza P, Yee MB, Kumar S, Milosevic J, Bloom DC, Arav-Boger R, Kinchington PR, Yolken R, Nimgaonkar V, D'Aiuto L.

Antiviral Res. 2015 Sep;121:16-23. doi: 10.1016/j.antiviral.2015.06.005. Epub 2015 Jun 12.

26.

Autoinduction of voriconazole metabolism in a child with invasive pulmonary aspergillosis.

Hsu AJ, Dabb A, Arav-Boger R.

Pharmacotherapy. 2015 Apr;35(4):e20-6. doi: 10.1002/phar.1566.

PMID:
25884532
27.

Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation.

Roy S, He R, Kapoor A, Forman M, Mazzone JR, Posner GH, Arav-Boger R.

Antimicrob Agents Chemother. 2015 Jul;59(7):3870-9. doi: 10.1128/AAC.00262-15. Epub 2015 Apr 13.

28.

Valganciclovir for symptomatic congenital cytomegalovirus disease.

Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

N Engl J Med. 2015 Mar 5;372(10):933-43. doi: 10.1056/NEJMoa1404599.

29.

Digitoxin analogues with improved anticytomegalovirus activity.

Cai H, Wang HY, Venkatadri R, Fu DX, Forman M, Bajaj SO, Li H, O'Doherty GA, Arav-Boger R.

ACS Med Chem Lett. 2014 Jan 25;5(4):395-9. doi: 10.1021/ml400529q. eCollection 2014 Apr 10.

30.

New cell-signaling pathways for controlling cytomegalovirus replication.

Roy S, Arav-Boger R.

Am J Transplant. 2014 Jun;14(6):1249-58. doi: 10.1111/ajt.12725. Epub 2014 May 19. Review.

31.

Activation of nucleotide oligomerization domain 2 (NOD2) by human cytomegalovirus initiates innate immune responses and restricts virus replication.

Kapoor A, Forman M, Arav-Boger R.

PLoS One. 2014 Mar 26;9(3):e92704. doi: 10.1371/journal.pone.0092704. eCollection 2014.

32.

In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.

Cai H, Kapoor A, He R, Venkatadri R, Forman M, Posner GH, Arav-Boger R.

Antimicrob Agents Chemother. 2014;58(2):986-94. doi: 10.1128/AAC.01972-13. Epub 2013 Nov 25.

33.

Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety.

He R, Forman M, Mott BT, Venkatadri R, Posner GH, Arav-Boger R.

Antimicrob Agents Chemother. 2013 Sep;57(9):4208-14. doi: 10.1128/AAC.00893-13. Epub 2013 Jun 17.

34.

Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study.

Mott BT, He R, Chen X, Fox JM, Civin CI, Arav-Boger R, Posner GH.

Bioorg Med Chem. 2013 Jul 1;21(13):3702-7. doi: 10.1016/j.bmc.2013.04.027. Epub 2013 Apr 22.

35.

Wnt modulating agents inhibit human cytomegalovirus replication.

Kapoor A, He R, Venkatadri R, Forman M, Arav-Boger R.

Antimicrob Agents Chemother. 2013 Jun;57(6):2761-7. doi: 10.1128/AAC.00029-13. Epub 2013 Apr 9.

36.

Human induced pluripotent stem cell-derived models to investigate human cytomegalovirus infection in neural cells.

D'Aiuto L, Di Maio R, Heath B, Raimondi G, Milosevic J, Watson AM, Bamne M, Parks WT, Yang L, Lin B, Miki T, Mich-Basso JD, Arav-Boger R, Sibille E, Sabunciyan S, Yolken R, Nimgaonkar V.

PLoS One. 2012;7(11):e49700. doi: 10.1371/journal.pone.0049700. Epub 2012 Nov 27. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/ea66e8f1-9f80-422f-8836-308a4cdc8ae4.

37.

Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.

Kapoor A, Cai H, Forman M, He R, Shamay M, Arav-Boger R.

Antimicrob Agents Chemother. 2012 Sep;56(9):4891-9. doi: 10.1128/AAC.00898-12. Epub 2012 Jul 9.

38.

Dried urine spots for detection and quantification of cytomegalovirus in newborns.

Forman M, Valsamakis A, Arav-Boger R.

Diagn Microbiol Infect Dis. 2012 Aug;73(4):326-9. doi: 10.1016/j.diagmicrobio.2012.04.009. Epub 2012 Jun 1.

39.

Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication.

He R, Park K, Cai H, Kapoor A, Forman M, Mott B, Posner GH, Arav-Boger R.

Antimicrob Agents Chemother. 2012 Jul;56(7):3508-15. doi: 10.1128/AAC.00519-12. Epub 2012 Apr 30.

40.

Polymorphisms in Toll-like receptor genes influence antibody responses to cytomegalovirus glycoprotein B vaccine.

Arav-Boger R, Wojcik GL, Duggal P, Ingersoll RG, Beaty T, Pass RF, Yolken RH.

BMC Res Notes. 2012 Mar 13;5:140. doi: 10.1186/1756-0500-5-140.

41.

An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities.

He R, Mott BT, Rosenthal AS, Genna DT, Posner GH, Arav-Boger R.

PLoS One. 2011;6(8):e24334. doi: 10.1371/journal.pone.0024334. Epub 2011 Aug 31.

42.

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors.

He R, Sandford G, Hayward GS, Burns WH, Posner GH, Forman M, Arav-Boger R.

Virol J. 2011 Jan 26;8:40. doi: 10.1186/1743-422X-8-40.

43.

Detection of a single identical cytomegalovirus (CMV) strain in recently seroconverted young women.

Murthy S, Hayward GS, Wheelan S, Forman MS, Ahn JH, Pass RF, Arav-Boger R.

PLoS One. 2011 Jan 10;6(1):e15949. doi: 10.1371/journal.pone.0015949.

44.

Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers.

Arav-Boger R, He R, Chiou CJ, Liu J, Woodard L, Rosenthal A, Jones-Brando L, Forman M, Posner G.

PLoS One. 2010 Apr 28;5(4):e10370. doi: 10.1371/journal.pone.0010370.

45.

Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia.

Jacobson LM, Milstone AM, Zenilman J, Carroll KC, Arav-Boger R.

Pediatr Infect Dis J. 2009 May;28(5):445-7. doi: 10.1097/INF.0b013e3181927891.

PMID:
19295462
46.

Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments.

Arav-Boger R.

Virus Genes. 2009 Apr;38(2):195-203. doi: 10.1007/s11262-008-0325-y. Epub 2009 Jan 13. Review.

PMID:
19139983
47.

The use of artificial neural networks in prediction of congenital CMV outcome from sequence data.

Arav-Boger R, Boger YS, Foster CB, Boger Z.

Bioinform Biol Insights. 2008 May 29;2:281-9.

48.

Viral load in congenital cytomegalovirus infection.

Arav-Boger R, Pass R.

Herpes. 2007 Jun;14(1):17-22. Review.

PMID:
17848214
49.
50.

Shwachman--Diamond syndrome associated with autoimmune phenomena.

Reif S, Arav-Boger R, Diamant S, Burstein Y, Fatal A.

J Med. 1999;30(3-4):259-65.

PMID:
17312679

Supplemental Content

Loading ...
Support Center